Gamcemetinib

Cat. No.:	HY-139504
CAS No.:	1887069-10-4
Molecular Formula:	$C_{22}H_{20}ClN_5O_3S$
Molecular Weight:	469.94
Target:	MAPKAPK2 (MK2)
Pathway:	MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 37.5 mg/mL (79.80 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1279 mL	10.6397 mL	21.2793 mL
	5 mM	0.4256 mL	2.1279 mL	4.2559 mL
	10 mM	0.2128 mL	1.0640 mL	2.1279 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1.5 mg/mL (3.19 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC_{50}=156.3 nM) and cell based assays (EC_{50}=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1[1].

IC_{50} & Target

MK2[1]

In Vitro

Gamcemetinib is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC_{50}=156.3 nM) and cell based assays (EC_{50}=89 nM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WO2020236636

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA